ALKBH5 suppresses malignancy of hepatocellular carcinoma via m6A-guided epigenetic inhibition of LYPD1

• Published in: Molecular cancer Vol. 19; no. 1; pp. 1 - 19
• Main Authors: Chen, Yunhao, Zhao, Yanchun, Chen, Junru, Peng, Chuanhui, Zhang, Yanpeng, Tong, Rongliang, Cheng, Qiyang, Yang, Beng, Feng, Xiaode, Lu, Yuejie, Xie, Haiyang, Zhou, Lin, Wu, Jian, Zheng, Shusen
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 10.08.2020; BioMed Central; BMC
• Subjects: ALKBH5; Antibodies; Cell proliferation; Demethylation; DNA methylation; Epigenetic inheritance; Epigenetics; Gene expression; Hepatocellular carcinoma; Hepatocellular carcinoma (HCC); Immunoprecipitation; Liver cancer; LYPD1; Malignancy; Medical prognosis; Medical research; Methyltransferases; N6-methyladenosine; N6-methyladenosine (m6A); Pathogenesis; Post-transcription; Proteins; Ribonucleic acid; RNA; RNA sequencing; Software; Statistical analysis; Tumor suppressor genes; Tumorigenesis; Tumorigenicity; Tumors; United States > US; China; Germany

Background N6-methyladenosine (m.sup.6A) modification is an emerging layer of epigenetic regulation which is widely implicated in the tumorigenicity of hepatocellular carcinoma (HCC), offering a novel perspective for investigating molecular pathogenesis of this disease. The role of AlkB homolog 5 (A...